Li Mou Zheng
Founder at AMOY DIAGNOSTICS CO., LTD.
Net worth: 265 M $ as of 2024-03-30
Profile
Li Mou Zheng is the founder of Amoy Diagnostics Co., Ltd., which was founded in 2008.
He currently holds the position of Chairman at Amoy Diagnostics Co., Ltd.
Additionally, Dr. Zheng is currently the Chairman at SinoPath Medical Investment (Beijing) Co., Ltd.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-09-29 | 87,701,616 ( 22.06% ) | 265 M $ | 2024-03-30 |
Li Mou Zheng active positions
Companies | Position | Start |
---|---|---|
AMOY DIAGNOSTICS CO., LTD. | Founder | 2008-02-20 |
SinoPath Medical Investment (Beijing) Co., Ltd.
SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Chairman | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
AMOY DIAGNOSTICS CO., LTD. | Health Technology |
Private companies | 1 |
---|---|
SinoPath Medical Investment (Beijing) Co., Ltd.
SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Health Services |
- Stock Market
- Insiders
- Li Mou Zheng